This study highlights the relationship between polyunsaturated fatty acids and cancer risk, suggesting blood biomarkers may be key for accurate assessment.
Madrigal plans to solidify Rezdiffra’s position in MASH despite start being slower than expected
In March 2024, Madrigal Pharmaceuticals had a breakthrough moment when, after years of research and anticipation, the US Food and Drug Administration (FDA) granted approval
August 13, 2024